Last updated: almost 2 years ago
AstraZeneca's Oncology Report: Challenges & Innovations in Lung Cancer Treatments
Explore AstraZeneca's recent MAA withdrawal for datopotamab deruxtecan, ongoing trials, and strategies in advancing lung cancer therapies.